文献速递急性肾损伤遗传性与小管间质肾病

继发性血栓性微血管病的流行病学、结局及补体基因变异

Epidemiology, Outcomes, and Complement Gene Variants in Secondary Thrombotic Microangiopathies.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-04-21

该研究纳入2009至2019年两家欧洲参考中心连续收治的336例首次血栓性微血管病(TMA)住院患者,继发性TMA占56%(188例),主要病因为造血干细胞移植(30%)、实体器官移植(23%)和恶性高血压(13%)。继发性TMA患者补体基因罕见变异检出率13%、致病或可能致病变异3%,均低于非典型溶血性尿毒症综合征(HUS)的65%和49%。中位随访1157天后,继发性TMA患者死亡或肾衰竭风险最高(校正HR 4.11,95%CI 2.00–8.46,P<0.001)。

要点

  • 继发性TMA是TMA主要病因(56%),以造血干细胞移植、实体器官移植和恶性高血压为主。
  • 继发性TMA补体基因致病或可能致病变异检出率仅3%,低于非典型HUS的49%。
  • 继发性TMA死亡或肾衰竭风险显著高于非典型HUS(校正HR 4.11,95%CI 2.00–8.46)。

核心结论

  • 继发性TMA是TMA的主要病因,且独立与死亡和进展至肾衰竭的高风险相关。

研究设计与样本

  • 研究为2009至2019年两家欧洲参考中心连续收治的首次TMA住院患者的队列研究,共336例。
  • 研究评估继发性TMA与其他TMA的相对发病率、临床和遗传谱及长期结局。

主要发现

  • 病因构成:非典型HUS 49例(15%)、血栓性血小板减少性紫癜(TTP)29例(9%)、志贺毒素相关HUS 70例(21%)、继发性TMA 188例(56%)。
  • 继发性TMA主要病因:造血干细胞移植56例(30%)、实体器官移植44例(23%)、恶性高血压25例(13%)。
  • 补体基因罕见变异:非典型HUS 32/49例(65%) vs 继发性TMA 8/64例(13%);致病或可能致病变异:非典型HUS 24/49例(49%) vs 继发性TMA 2/64例(3%),P<0.001。
  • 中位随访1157天后,死亡或肾衰竭:非典型HUS 14例(29%)、TTP 8例(28%)、志贺毒素相关HUS 5例(7%)、继发性TMA 121例(64%)。
  • 以非典型HUS为参照,继发性TMA死亡或肾衰竭风险最高:未校正HR 3.35(95%CI 1.85–6.07,P<0.001),校正HR 4.11(95%CI 2.00–8.46,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The identification of complement defects as major drivers of primary atypical hemolytic uremic syndrome (HUS) has transformed the landscape of thrombotic microangiopathies (TMAs), leading to the development of targeted therapies and better patient outcomes. By contrast, little is known about the presentation, genetics, and outcomes of TMA associated with specific diseases or conditions, also referred to as secondary TMA. METHODS: In this study, we assessed the relative incidence, clinical and genetic spectra, and long-term outcomes of secondary TMA versus other TMAs in consecutive patients hospitalized with a first episode of TMA from 2009 to 2019 at two European reference centers. RESULTS: During the study period, 336 patients were hospitalized with a first episode of TMA. Etiologies included atypical HUS in 49 patients (15%), thrombotic thrombocytopenic purpura (TTP) in 29 (9%), shigatoxin-associated HUS in 70 (21%), and secondary TMA in 188 (56%). The main causes of secondary TMA were hematopoietic stem-cell transplantation ( n =56, 30%), solid-organ transplantation ( n =44, 23%), and malignant hypertension ( n =25, 13%). Rare variants in complement genes were identified in 32 of 49 patients (65%) with atypical HUS and eight of 64 patients (13%) with secondary TMA; pathogenic or likely pathogenic variants were found in 24 of 49 (49%) and two of 64 (3%) of them, respectively ( P < 0.001). After a median follow-up of 1157 days, death or kidney failure occurred in 14 (29%), eight (28%), five (7%), and 121 (64%) patients with atypical HUS, TTP, shigatoxin-associated HUS, and secondary TMA, respectively. Unadjusted and adjusted Cox regressions showed that patients with secondary TMA had the highest risk of death or kidney failure (unadjusted hazard ratio [HR], 3.35; 95% confidence interval [CI], 1.85 to 6.07; P < 0.001; adjusted HR, 4.11; 95% CI, 2.00 to 8.46; P < 0.001; considering atypical HUS as reference). CONCLUSIONS: Secondary TMAs represent the main cause of TMA and are independently associated with a high risk of death and progression to kidney failure.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Werion A, Storms P, Zizi Y, et al. Epidemiology, Outcomes, and Complement Gene Variants in Secondary Thrombotic Microangiopathies. Clin J Am Soc Nephrol. 2023. PMID: 37094330. doi:10.2215/CJN.0000000000000182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。